We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy.
- Authors
Donertas, Basak; Unel, Cigdem Cengelli; Erol, Kevser
- Abstract
Cisplatin is a widely used antineoplastic agent in the treatment of various cancers. Peripheral neuropathy is a well-known side effect of cisplatin and has the potential to result in limiting and/or reducing the dose, decreasing the quality of life. Unfortunately, the mechanism for cisplatin-induced neuropathy has not been completely elucidated. Currently, available treatments for neuropathic pain (NP) are mostly symptomatic, insufficient and are often linked with several detrimental side effects; thus, effective treatments are needed. Cannabinoids and agmatine are endogenous modulators that are implicated in painful states. This review explains the cisplatin-induced neuropathy and antinociceptive effects of cannabinoids and agmatine in animal models of NP and their putative therapeutic potential in cisplatin-induced neuropathy and antinociceptive effects of cannabinoids and agmatine in animal models of NP and their putative therapeutic potential in cisplatin-induced neuropathy.
- Publication
Journal of Experimental Pharmacology, 2018, Vol 10, p19
- ISSN
1179-1454
- Publication type
Article
- DOI
10.2147/JEP.S162059